SCHEMBL23788970

SCHEMBL23788970

Cc1cc(N(C)C)nc(Nc2ccc(CNC(=O)Cc3ccccc3)cc2)n1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.78
SLC2A1 P11166 2/20 0.62
TAAR1 Q96RJ0 1/20 0.60
ALDH1A1 P00352 4/20 0.48
LMNA P02545 4/20 0.47
NPC1 O15118 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 4/20 0.46
RAB9A P51151 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 3/20 0.46
HTT P42858 3/20 0.46
USP2 O75604 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
RET P07949 1/20 0.45
ERCC1 P07992 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23789082 0.88 TGM2 (1.00) TGM2SLC2A1TAAR1LMNANPC1
SCHEMBL23788965 0.86 TGM2 (0.64) TGM2SLC2A1TAAR1ALDH1A1NPC1
SCHEMBL23788967 0.86 TGM2 (0.67) TGM2SLC2A1TAAR1ALDH1A1LMNA
SCHEMBL23789092 0.82 TGM2 (0.84) TGM2SLC2A1TAAR1ALDH1A1LMNA
SCHEMBL23789090 0.82 TGM2 (0.73) TGM2SLC2A1TAAR1LMNANPC1
SCHEMBL23789091 0.81 TGM2 (0.84) TGM2SLC2A1TAAR1LMNANPC1
SCHEMBL23789093 0.78 TGM2 (0.82) TGM2SLC2A1TAAR1LMNANPC1
SCHEMBL23788964 0.75 TAAR1 (0.69) TGM2SLC2A1TAAR1LMNANPC1
SCHEMBL23788966 0.74 TGM2 (0.59) TGM2SLC2A1TAAR1LMNAMAPT
SCHEMBL3244319 0.74 TGM2 (0.68) TGM2SLC2A1TAAR1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276960-A1 INHIBITORS OF TISSUE TRANSGLUTAMINASE 2 (TG2) AND USES THEREOF NORTHWESTERN UNIVERSITY 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210276960-A1 INHIBITORS OF TISSUE TRANSGLUTAMINASE 2 (TG2) AND USES THEREOF TGM2, TGM3, TGM6 TGM2 1/4885SLC2A1 550/4885TAAR1 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.